Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

Explore the fierce competition between Novo Nordisk and Pfizer as they vie for Metsera amidst a booming obesity drug market.

By Maggie Fick LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an ...

Reuters further highlighted that Novo Nordisk A/S (NYSE:NVO), which initially celebrated the success of its obesity drug, has ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Novo Nordisk has launched an audacious bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's earlier takeover ...

Novo Nordisk raises its bid for obesity drugmaker Metsera to outmanoeuvre Pfizer, reshaping the fast-growing weight-loss ...